Pharma Focus Asia

AstraZeneca Sells U.S. gout Drug Rights to Ironwood for up to $265 million

Wednesday, April 27, 2016

British drugmaker AstraZeneca Plc said on Tuesday Ironwood Pharmaceuticals Inc (IRWD.O) would buy the U.S. marketing rights for its newly approved gout drug for up to $265 million.

The deal gives Ironwood the rights to sell the drug, Zurampic, or lesinurad, which was approved in the United States last year to treat high levels of uric acid in the blood of patients suffering from gout.

The agreement also covers rights to a fixed-dose combination of lesinurad and allopurinol.

U.S.-based Ironwood said it would make an upfront payment of $100 million to AstraZeneca, plus sales-related and other milestones of up to $165 million. Ironwood will also pay AstraZeneca tiered single-digit royalties on product sales.

AstraZeneca has a strategy of selling certain rights to non-core medicines to help pay the bills as it invests in new drugs and copes with the loss of patent protection on a raft of former blockbusters.

Such "externalization" deals contributed $1.1 billion to revenue last year and the company has said the figure is likely to be higher in 2016.

 

Source : reuters.com

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024